Subgroup Could Give Xpovio Focused Commercial Opportunity In Endometrial Cancer
Executive Summary
Karyopharm’s Phase III SIENDO study showed what analysts called a “modest” progression-free survival improvement overall, but a fourfold improvement in patients with wild-type p53.
You may also be interested in...
Xpovio’s Solid Tumor Debut Faces Likely Three-Year Delay
Karyopharm will conduct another trial of the drug in p53 wild-type endometrial cancer after the FDA said SIENDO data were insufficient for approval.
Bumpy EU Review Ends Well For Selinexor Filing
Karyopharm says its treatment for patients with refractory multiple myeloma could become its first product to be approved in Europe.
Karyopharm’s Xpovio In Multiple Myeloma Priced At $22,000 Per Four-Week Cycle
Immediate interaction with US FDA after stressful advisory committee facilitated accelerated approval in fourth-line myeloma, company says. Four different dosing regimens will be priced at $22,000 for four weeks.